Emyria (ASX:EMD) says it has qualified eight sites across Australia to support the pivotal Phase 3 clinical trial of EMD-RX5.
EMD-RX5 is the company's first ultra-pure cannabinoid (CBD) treatment.
The company said results from the Phase 3 trial are expected to support an initial registration of EMD-RX5 as a Schedule 3, over-the-counter treatment in Australia.
Emyria’s managing director, Dr Michael Winlo, said, “We have had exceptional demand to participate in our Phase 3 program from clinical sites across Australia. We take this as a strong sign that there is high clinical interest in our unique Ultra-Pure CBD capsule and strong patient need for new treatment options for our target indication - the symptoms of psychological distress.